Results 211 to 220 of about 10,725 (262)
Some of the next articles are maybe not open access.
Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension
New England Journal of Medicine, 2005Sildenafil inhibits phosphodiesterase type 5, an enzyme that metabolizes cyclic guanosine monophosphate, thereby enhancing the cyclic guanosine monophosphate-mediated relaxation and growth inhibition of vascular smooth-muscle cells, including those in the lung.In this double-blind, placebo-controlled study, we randomly assigned 278 patients with ...
Ardeschir Ghofrani +2 more
exaly +3 more sources
Sildenafil citrate-Associated priapism
Urology, 2000We report the first case of priapism associated with the use of sildenafil citrate. The patient was a 28-year-old man with mild erectile dysfunction after penile trauma who self-treated with a 100-mg dose of sildenafil citrate, resulting in low-flow priapism. After aspiration and intracorporal injection of alpha-agonists, the priapism resolved.
R L, Sur, C J, Kane
openaire +2 more sources
Viagra® (sildenafil citrate) and ophthalmology
Progress in Retinal and Eye Research, 2002Viagra (sildenafil citrate) improves penile erections in men with erectile dysfunction (ED) by selectively inhibiting cGMP-specific phosphodiesterase type 5 (PDE5), which is present in all vascular tissue. It also exerts a minor inhibitory action against PDE6, which is present exclusively in rod and cone photoreceptors.
Alan, Laties, Eberhart, Zrenner
openaire +2 more sources
Intensive and Critical Care Nursing, 1999
Sildenafil is the first of a series of orally active treatments for MED which has resulted in unprecedented demand for treatment and potentially high cost to the NHS. Further oral therapies are likely to follow in the next year or so. In clinical trials, sildenafil produced an erection (sufficient to achieve intercourse) lasting up to 4 h on around 70%
openaire +2 more sources
Sildenafil is the first of a series of orally active treatments for MED which has resulted in unprecedented demand for treatment and potentially high cost to the NHS. Further oral therapies are likely to follow in the next year or so. In clinical trials, sildenafil produced an erection (sufficient to achieve intercourse) lasting up to 4 h on around 70%
openaire +2 more sources
Sildenafil citrate (Viagra(R))
Drugs of Today, 2000Sildenafil citrate, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type V (PDE V), initially designated as compound 92-480-10 by Pfizer, was studied in the late 1980s as an antianginal. An unexpected side effect of the early clinical investigations was improved erectile function among the men studied.
openaire +2 more sources
Sildenafil citrate: A therapeutic update
Clinical Therapeutics, 2001Since its approval by the US Food and Drug Administration in March 1998, sildenafil citrate has been used by millions of men for the treatment of erectile dysfunction. Recent studies and consensus reports have expanded our understanding of its efficacy, safety, contraindications, and drug interactions.This paper reviews recent studies of the efficacy ...
E G, Boyce, E M, Umland
openaire +2 more sources
Physicochemical Properties of Sildenafil Citrate (Viagra) and Sildenafil Base
Journal of Pharmaceutical Sciences, 2003Sildenafil citrate (Viagra) [I] and sildenafil base [II] are easily and unequivocally characterized by a set of physicochemical methods that include X-ray diffractometry, infrared spectroscopy, and thermal analysis. Monoclinic lattice constants: [I]: a = 26.98 A; b = 11.95 A; c = 16.68 A; beta = 106.97 degrees. [II]: a = 8.66 A; b = 34.27 A; c = 8.93 A;
Melnikov, P. +4 more
openaire +3 more sources
The Lancet, 1998
Sir—In your editorial on sildenafil citrate (Viagra), you state that “Public information to consumers and health professionals covers safety adequately, if not to the total satisfaction of consumer groups such as the US Public Citizen”. Although this editorial involved an internet search, we point out information that is not in the FDA-approved label ...
Sidney M Wolfe +2 more
openaire +1 more source
Sir—In your editorial on sildenafil citrate (Viagra), you state that “Public information to consumers and health professionals covers safety adequately, if not to the total satisfaction of consumer groups such as the US Public Citizen”. Although this editorial involved an internet search, we point out information that is not in the FDA-approved label ...
Sidney M Wolfe +2 more
openaire +1 more source
Overall cardiovascular profile of sildenafil citrate
The American Journal of Cardiology, 1999Sildenafil, a selective inhibitor of phosphodiesterase type 5 (PDE5), is the first in a new class of orally effective treatments for erectile dysfunction. During sexual stimulation, the cavernous nerves release nitric oxide (NO), which induces cyclic guanosine monophosphate (cGMP) formation and smooth muscle relaxation in the corpus cavernosum ...
R M, Zusman +3 more
openaire +2 more sources
SILDENAFIL CITRATE AFTER RADICAL RETROPUBIC PROSTATECTOMY
Journal of Urology, 1999Erectile dysfunction continues to be a significant problem for men after radical retropubic prostatectomy despite nerve sparing techniques. Sildenafil citrate (Viagra) has proved effective for erectile dysfunction in many men. We determine the efficacy of sildenafil in men with erectile dysfunction after radical retropubic prostatectomy and examine ...
B H, Lowentritt +7 more
openaire +2 more sources